Clinical Trials Logo

Neuroendocrine Tumors clinical trials

View clinical trials related to Neuroendocrine Tumors.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT04814732 No longer available - Clinical trials for Neuroendocrine Tumors

Expanded Access Program of Surufatinib

Start date: n/a
Phase:
Study type: Expanded Access

This treatment protocol is intended to provide early access of surufatinib to patients with locally advanced or metastatic NETs for whom, in the opinion of their treating physician, other treatment options or surufatinib clinical trials in this indication are unsuitable. This EAP is currently available in the US only.

NCT ID: NCT02431715 No longer available - Neuroblastoma Clinical Trials

18F-FDOPA PET in Neuroendocrine Tumours

Start date: n/a
Phase:
Study type: Expanded Access

Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic. The correct treatment approach is dependent on the extent of the disease, however surgical approaches and systemic therapy can be curative. Combined positron emission tomography/computed tomography (PET/CT) using the radiotracer 18F-6-L-fluorodihydroxyphenylalanine (18F-FDOPA) has been shown to be a promising non-invasive technique to help localizing NETs and guide their treatment.

NCT ID: NCT02375464 No longer available - Clinical trials for Neuroendocrine Tumors

Gallium-68 DOTATOC for Management of Neuroendocrine Tumors

Start date: April 2015
Phase: Phase 3
Study type: Expanded Access

Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs.

NCT ID: NCT02358018 No longer available - Clinical trials for Neuroendocrine Tumors

68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial

Start date: n/a
Phase: N/A
Study type: Expanded Access

The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor. 68Ga-DOTATOC is an improved imaging agent being routinely used in many centers outside the USA, with better tumor detection than with OctreoScan.

NCT ID: NCT02174679 No longer available - Clinical trials for Neuroendocrine Tumors

68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Start date: n/a
Phase:
Study type: Expanded Access

To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

NCT ID: NCT01980732 No longer available - Carcinoid Tumors Clinical Trials

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Start date: n/a
Phase: N/A
Study type: Expanded Access

The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.